Please try another search
For the six months ended 30 June 2016, Pharmstandard PAO revenues increased 86% to RUR28.38B. Net income increased 30% to RUR4.7B. Revenues reflect Pharmaceutical Products OTC segment increase of 88% to RUR27.78B, Medical Equipment and Disposables segment increase of 23% to RUR594.3M. Basic Earnings per Share excluding Extraordinary Items increased from RUR99.28 to RUR129.35.
Period Ending: | Jun 30, 2016 | Dec 31, 2015 | Jun 30, 2015 | Dec 31, 2014 |
---|---|---|---|---|
Total Revenue | 28376.64 | 31927.73 | 15267.21 | 24018.11 |
Gross Profit | 10049.17 | 11322.74 | 6474.6 | 9080.94 |
Operating Income | 5856.5 | 13010.04 | 4667.83 | 9035.84 |
Net Income | 4702.64 | 10140.01 | 3609.45 | 7327.3 |
Period Ending: | Jun 30, 2016 | Dec 31, 2015 | Jun 30, 2015 | Dec 31, 2014 |
---|---|---|---|---|
Total Assets | 88941.16 | 82621.62 | 66634.47 | 62820.47 |
Total Liabilities | 31005.88 | 28957.66 | 23904.29 | 23646.08 |
Total Equity | 57935.28 | 53663.96 | 42730.18 | 39174.39 |
Period Ending: | Jun 30, 2016 | Dec 31, 2015 | Jun 30, 2015 | Dec 31, 2014 |
---|---|---|---|---|
Period Length: | 6 Months | 12 Months | 6 Months | 12 Months |
Cash From Operating Activities | -3074.8 | 15625.19 | 3310.47 | 9615.93 |
Cash From Investing Activities | -5832.89 | -9896.02 | -6472.16 | -9886.68 |
Cash From Financing Activities | -7 | 35.13 | -46.72 | -6554.06 |
Net Change in Cash | -8934.94 | 5847.03 | -3208.41 | -6823.33 |
Unlock access to over 1000 metrics with InvestingPro
View advanced insights on financial statements, including growth rates and metrics that provide an in-depth view of the company's historical and forecasted financial performance.
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review